Physician profile
Robert A Marsh
NPI 1992986434
$8,765.56
in general payments reported to CMS, 2019-2025
13 companies · $403 in 2025
The $403 reported for 2025 was less than what a typical Neurological Surgery provider received nationally (typical 2025 total: $604).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,667 · 2020: $2,117 · 2021: $320 · 2022: $157 · 2023: $349 · 2024: $2,753 · 2025: $403.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Travel and Lodging: $1,887 · Food and Beverage: $1,618.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Travel and Lodging | $1,886.80 |
| Food and Beverage | $1,617.68 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Aesculap, INC. | $2,143.37 | 2019 | |
| Si-Bone, INC. | $1,965.01 | 2019-2025 | |
| Mid-Atlantic Surgical Systems, LLC | $1,813.49 | 2024-2025 | |
| Globus Medical, INC. | $629.65 | 2020-2025 | Excelsiusgps Robotic Navigation System, Excelsius Gps, Creo 5.5 |
| Integrity Implants INC. | $584.29 | 2020 | |
| Arthrex, INC. | $508.61 | 2024-2025 | |
| Stryker Corporation | $344.11 | 2019-2023 | Tritanium |
| Kerecis Limited | $259.39 | 2024-2025 | Kerecis Omega3 Marigen, Kerecis Omega3 Surgiclose, Kerecis Omega3 Graftguide |
| Cerapedics INC. | $247.12 | 2021-2024 | I-Factor Peptide Enhanced Bone Graft |
| Abbott Laboratories | $203.73 | 2019-2025 | Eterna |
| Mml US, INC. | $24.87 | 2025 | Reactiv8 |
| Ulrich Medical USA, INC. | $23.50 | 2019 | |
| Ethicon US, LLC | $18.42 | 2025 | Surgicel Nu-Knit, Vistaseal, Surgiflo Hemostatic Matrix |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Marsh listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.